We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Expanded Range of Quality Control Sera Ensures Reliable Results

By LabMedica International staff writers
Posted on 10 Aug 2009
An expanded range of quality control sera ensures reliable results for the clinical laboratory, as well as being timesaving and economic. More...


Called Acusera, the new range includes controls for blood gas, coagulation, drugs of abuse, heart (liquid cardiac), liquid clinical chemistry, maternal screening, tumor markers, and urinalysis.

Acusera, produced by Randox (Crumlin, UK), is supplied with accurate instrument and method-specific values. Bottles, caps, and packaging are color-coded to help distinguish different analyte levels and minimize errors. Quality-control materials can be used alongside Randox reagents or as third-party controls from an independent manufacturer. Randox also offers quality-control materials tailored to customers' specifications.

Randox is an international diagnostics company, which develops, manufactures, and markets clinical diagnostic products worldwide. Core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; and recombinant proteins and antibodies.

Related Links:
Randox




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.